Correlation Between Telix Pharmaceuticals and OnKure Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Telix Pharmaceuticals and OnKure Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Telix Pharmaceuticals and OnKure Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Telix Pharmaceuticals Limited and OnKure Therapeutics,, you can compare the effects of market volatilities on Telix Pharmaceuticals and OnKure Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Telix Pharmaceuticals with a short position of OnKure Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Telix Pharmaceuticals and OnKure Therapeutics,.

Diversification Opportunities for Telix Pharmaceuticals and OnKure Therapeutics,

-0.16
  Correlation Coefficient

Good diversification

The 3 months correlation between Telix and OnKure is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Telix Pharmaceuticals Limited and OnKure Therapeutics, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on OnKure Therapeutics, and Telix Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Telix Pharmaceuticals Limited are associated (or correlated) with OnKure Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of OnKure Therapeutics, has no effect on the direction of Telix Pharmaceuticals i.e., Telix Pharmaceuticals and OnKure Therapeutics, go up and down completely randomly.

Pair Corralation between Telix Pharmaceuticals and OnKure Therapeutics,

Considering the 90-day investment horizon Telix Pharmaceuticals Limited is expected to generate 0.52 times more return on investment than OnKure Therapeutics,. However, Telix Pharmaceuticals Limited is 1.91 times less risky than OnKure Therapeutics,. It trades about -0.08 of its potential returns per unit of risk. OnKure Therapeutics, is currently generating about -0.46 per unit of risk. If you would invest  1,619  in Telix Pharmaceuticals Limited on October 4, 2024 and sell it today you would lose (79.00) from holding Telix Pharmaceuticals Limited or give up 4.88% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Telix Pharmaceuticals Limited  vs.  OnKure Therapeutics,

 Performance 
       Timeline  
Telix Pharmaceuticals 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Telix Pharmaceuticals Limited are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong essential indicators, Telix Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
OnKure Therapeutics, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days OnKure Therapeutics, has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Telix Pharmaceuticals and OnKure Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Telix Pharmaceuticals and OnKure Therapeutics,

The main advantage of trading using opposite Telix Pharmaceuticals and OnKure Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Telix Pharmaceuticals position performs unexpectedly, OnKure Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OnKure Therapeutics, will offset losses from the drop in OnKure Therapeutics,'s long position.
The idea behind Telix Pharmaceuticals Limited and OnKure Therapeutics, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Fundamental Analysis
View fundamental data based on most recent published financial statements
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals